【IHH 5225 交流专区】综合保健控股

哭哭鸟

Loading FB Video...

icy97

IHH HEALTHCARE BERHAD

Date of change	31 Dec 2019
Name	DR TAN SEE LENG
Age	54
Gender	Male
Nationality	Singapore
Designation	Managing Director
Directorate	Executive
Type of change	Others
Description	Dr Tan See Leng ("Dr Tan") shall cease as the Managing Director and Chief Executive Officer of IHH Healthcare Berhad ("IHH") at the expiry of his contract of employment on 31 December 2019.

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Professional Qualification	Fellow	College of Family Physicians, Singapore
2	Professional Qualification	Fellow	Academy of Medicine, Singapore
3	Masters	Business Administration	University of Chicago Booth School of Business
4	Masters	Medicine (Family Medicine)	National University of Singapore
5	Degree	Bachelor of Medicine and Bachelor of Surgery (MBBS)	National University of Singapore

Working experience and occupation	Dr Tan was appointed the Managing Director and Chief Executive Officer ("CEO") of IHH in January 2014 after serving as an Executive Director on the IHH Board for 2 years. Dr Tan is currently the Group CEO and Managing Director of Parkway Pantai Limited, a position he assumed in 2011. He also serves on the Boards of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. ("ASYH") Group and on a Board Committee of ASYH. He also serves on the Advisory Board of Lee Kong Chian School of Business at Singapore Management University and on the Board of Parkway Trust Management Limited ("PTM"), an indirect wholly-owned subsidiary of IHH. PTM manages Parkway Life Real Estate Investment Trust, which is listed on the Singapore Exchange Securities Trading Limited.Prior to this, Dr Tan was the CEO of Parkway Holdings Limited from April 2010, a position he rose to fairly quickly after he joined Parkway in 2004 as Chief Operating Officer of Mount Elizabeth Hospital. As a young entrepreneur, Dr Tan founded a private primary healthcare group at the age of 27 and subsequently developed it into the second largest primary healthcare group in Singapore before successfully selling the company to a leading global health-plan and insurance provider.With over 27 years of healthcare experience, Dr Tan has served as an active member of various medical committees, such as Singapore Ministry of Health's MediShield Life Review Committee. He has been reappointed Adjunct Assistant Professor of Duke-NUS Graduate Medical School Singapore, Office of Education, for the period until 2019.
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Dr Tan's interest as at 27 May 2019 is as follows: Direct interest in IHH: 1) 2,863,300 ordinary shares 2) 1,308,000 Long Term Incentive Plan units 3) 20,661,000 Enterprise Option Scheme optionsDirect interest in a subsidiary:Parkway Pantai Limited [USD500 million 4.25% Senior Perpetual Securities] - Value of securities held: USD3,000,000

icy97

Date of change	01 Jul 2019
Name	DR KELVIN LOH CHI-KEON
Age	45
Gender	Male
Nationality	Singapore
Designation	Executive Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	Business Administration	National University of Singapore Business School
2	Degree	Bachelor of Medicine and Bachelor of Surgery	National University of Singapore

Working experience and occupation	Dr Kelvin Loh Chi-Keon ("Dr Kelvin Loh") joins IHH Healthcare Berhad ("IHH") from Columbia Asia Group where he was Chief Executive Officer ("CEO"). Dr Kelvin Loh started his career as a practicing physician before serving for 10 years in the public sector in Singapore, in areas such as clinical services development, hospital planning and hospital operations. Dr Kelvin Loh previously joined the IHH Group in 2008, and between 2008 and 2017 held a number of senior management roles, before taking over as CEO for the Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East.Dr Kelvin Loh moved to Columbia Asia Group as CEO in 2017 where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia including Malaysia and India. Dr Kelvin Loh is a senior healthcare executive with strong track record of delivery. He has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in diverse countries across Asia.
Directorships in public companies and listed issuers (if any)	Nil
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Dr Kelvin Loh's interest as at 27 May 2019 is as follows: Direct interest in a subsidiary:Parkway Life Real Estate Investment Trust - 120,000 units

Remarks :

Dr Kelvin Loh will assume the position of Managing Director and Chief Executive Officer of IHH with effect from 1 January 2020, to succeed Dr Tan See Leng upon the completion of his contract period on 31 December 2019. Prior to the effective date of his appointment on 1 January 2020, Dr Kelvin Loh will be joining the IHH Group as CEO (designate) and Executive Director to undertake a transitionary process from 1 July 2019 onwards.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2019	31 Mar 2018	31 Mar 2019	31 Mar 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,642,687	2,854,953	3,642,687	2,854,953
2	Profit/(loss) before tax	187,086	89,878	187,086	89,878
3	Profit/(loss) for the period	-8,942	29,151	-8,942	29,151
4	Profit/(loss) attributable to ordinary equity holders of the parent	89,510	57,235	89,510	57,235
5	Basic earnings/(loss) per share (Subunit)	0.78	0.44	0.78	0.44
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.5000		2.5100

icy97

IHH HEALTHCARE BERHAD

Particulars of substantial Securities Holder

Name	MITSUI & CO., LTD.
Address	1-3, Marunouchi 1-Chome, Chiyoda-ku, Tokyo 100-8631 Japan.
Company No.	1010001008767
Nationality/Country of incorporation	Japan
Descriptions (Class)	Ordinary shares

Details of changes

No	Date of change	No of securities	Type of Transaction	Nature of Interest
1	18 Jun 2019	2,888,487,400	Transferred	Direct Interest
	Name of registered holder	Mitsui & Co., Ltd.
	Address of registered holder	1-3, Marunouchi 1-Chome, Chiyoda-ku Tokyo 100-8631, Japan
	Description of "Others" Type of Transaction
2	18 Jun 2019	2,888,487,400	Transferred	Indirect Interest
	Name of registered holder	MBK Healthcare Management Pte Ltd
	Address of registered holder	8 Robinson Road, #14-00, ASO Building, Singapore 048544
	Description of "Others" Type of Transaction

Circumstances by reason of which change has occurred	Change from direct to indirect holding of shares due to the transfer of 2,888,487,400 shares in IHH Healthcare Berhad from Mitsui & Co., Ltd. to MBK Healthcare Management Pte Ltd, wholly-owned subsidiary of Mitsui & Co., Ltd.
Nature of interest	Direct and Indirect Interest
Direct (units)	0
Direct (%)	0
Indirect/deemed interest (units)	2,888,487,400
Indirect/deemed interest (%)	32.921
Total no of securities after change	2,888,487,400
Date of notice	18 Jun 2019
Date notice received by Listed Issuer	18 Jun 2019

icy97

Notice of Interest Sub. S-hldr (Section 137 of CA 2016)

IHH HEALTHCARE BERHAD

Particulars of Substantial Securities Holder

Name	MBK HEALTHCARE MANAGEMENT PTE LTD
Address	8 Robinson Road, #14-00, ASO Building, 048544 Singapore.
Company No.	201302906D
Nationality/Country of incorporation	Singapore
Descriptions (Class)	Ordinary shares
Name & address of registered holder	MBK Healthcare Management Pte Ltd8 Robinson Road,#14-00, ASO Building, Singapore 048544

Date interest acquired & no of securities acquired
Date interest acquired	18 Jun 2019
No of securities	2,888,487,400
Circumstances by reason of which Securities Holder has interest	Transfer of 2,888,487,400 shares in IHH Healthcare Berhad from Mitsui & Co., Ltd., the holding company of MBK Healthcare Management Pte Ltd, to MBK Healthcare Management Pte Ltd.
Nature of interest	Direct Interest
Total no of securities after change
Direct (units)	2,888,487,400
Direct (%)	32.921
Indirect/deemed interest (units)
Indirect/deemed interest (%)
Date of notice	18 Jun 2019
Date notice received by Listed Issuer	18 Jun 2019

icy97

优化架构节省更多-ihh医疗看好富通业绩改善
https://www.enanyang.my/news/20190804/优化架构节省更多-brihh医疗看好富通业绩改善/

icy97

新CEO大刀阔斧·富通要砍20%开销
https://www.sinchew.com.my/content/content_2103598.html

（吉隆坡20日讯）IHH医保（IHH,5225,主板医疗保健组）买下的富通医疗（Fortis）称，在前持有人卷走超过2亿令吉钜款后，新任首席执行员将计划削减五分之一成本，以重振这家印度第二大的医院连锁集团。

未来两年拟减1.3亿开支

今年3月接任富通医疗首席执行员的阿舒托斯日前在新德里郊外总部接受《彭博社》访问时指出，他的目标是在未来两年内削减3100万美元（约1亿3000万令吉）开支，同时8400万美元（约3亿5100万令吉）新资本开销也即将到位。

目前富通医疗正寻求节省开销，从节能灯到自动化其业务分析部，甚至重新谈判医生工资等以节省开支。阿舒托斯表示，这是新的富通，他以自己办公室为例，所有家具都被会议桌所取代，以将办公室空间兼作会议室，使它简单、整洁与透明化。

这些仅是阿舒托斯将富通医疗重新恢复健全的第一步。较早时，该公司前持有人马威达星及西威达星被印度监管机构揭发，从公司卷走40亿卢比（约2亿3400万令吉）。

这导致现金短缺的富通医疗掀起一场激烈的竞购战，最终大马的IHH医保脱颖而出，赢得富通医疗的控制性股权。

IHH医保对富通医疗做的第一件事，就是注入400亿卢比资金以稳定其业务。之后聘请了阿舒托斯担任首席执行员，他原是另一家医院连锁集团纳拉亚那胡达亚拉耶的首席执行员，后者是以其超高效率实现最低成本而闻名全球，预料他将在富通医疗“重施故技”。

IHH医保所提供的大部份资金，马上进行收购驻新加坡的产业信托公司，后者充当富通医院的业主攫取租金款项，并在取消租金付款后将提高富通医疗的赚钱能力。

阿舒托斯也计划与医生谈判“互惠互利”的薪酬，同时还把一个研究病人住院期团队的工作，由软件代替。

该公司计划脱售或关闭表现欠佳的设施，及退出管理他人医院的合约，并表示它们将分散公司的专注力，该公司也在探索出售非必要资产，如它在斯里兰卡医院的股份。

最新一季盈利倍增

富通医疗将在未来3年，投资60亿卢比的资本开销，主要充当扩大产能，以及为其加尔各答、班加罗尔和新德里附近现有医院，增加新技术和医疗法。并且将在金奈设立新的200床位设施，它之前因缺乏资金而延迟推行。

根据《彭博社》资料，富通医疗在连续6个季度亏损后，在IHH医保及新首席执行员管理下，过去2季皆转亏为盈。本月初宣布的最新一季业绩显示，旗下的医院业务盈利比前期增加了近倍。

富通医疗即使有了“大刀阔斧”整顿新计划，惟仍然没有完全抛弃过去的一些弊端，如该公司已经注销了前持有人据称骗走的资金。该公司仍在努力设法取回有关损失，包括采取法律程序向前拥有人索回7300万美元的款项。阿舒托斯表示，有关款项对富通医疗很重要，这等于公司2年的资本开销。


文章来源 ： 星洲日报 2019-08-20

icy97

新收购和医院业务推高营业额 IHH次季净利升12%
Justin Lim/theedgemarkets.com
August 30, 2019
https://www.theedgemarkets.com/article/新收购和医院业务推高营业额-ihh次季净利升12

（吉隆坡30日讯）IHH医疗保健（IHH Healthcare Bhd）第二季净利按年上升12%，因该集团继续计入去年最后一个季度完成的两项收购的贡献。

这家亚洲最大医院营运商今日向大马交易所报备，截至6月杪次季净利报1亿8499万令吉，或每股1.86仙，高于上财年同期的1亿6511万令吉，或每股1.75仙。

除了Amanjaya Specialist Centre（去年10月完成）和Fortis Healthcare（一个月后购得）的收购，双双于2017年3月开业的香港鹰阁医院（Gleneagles Hong Kong Hospital）和土耳其Acibadem Altunizade Hospital的盈利继续提高，以及其他现有业务的内部增长，亦推高盈利。

次季营业额从26亿6000万令吉，劲扬37%至36亿5000万令吉，而扣除利息、税项、折旧及摊销盈利（EBITDA）上涨47%。

标青的次季表现，推高2019财政年首半年净利至2亿7450万令吉，较同期的2亿2234万令吉，按年增长23%；营业额由55亿1000万令吉，扬32%至72亿9000万令吉。

IHH董事经理兼总执行长陈诗龙在文告中表示，该集团在严格执行策略的同时，交出了强劲的表现，将为IHH下一段增长奠定良好的基础。

“在印度，我们对Fortis重组计划的持续进展感到满意。Fortis连续第二个季度实现税前营运盈利，同时取得更高的营业额，并支撑资产负债表。管理层充分相信，这一转型收购将在未来几年继续为IHH带来增长。”

他补充，该集团积极采取措施削减Acibadem的非里拉债务，也降低了外汇波动对IHH收益的影响。至于大中华区，除了香港鹰阁持续增长，该集团期待将在未来18个月开业的成都鹰阁和上海鹰阁。

展望未来，该集团表示，土耳其持续的政治不确定将给该国的经济活动带来压力，并导致汇率波动，而大马、新加坡和印度即将实施的价格管制可能会影响获利，从而造成监管风险。

不过，IHH称，其经验丰富的管理团队拥有良好的执行记录，并预计将继续为所有利益相关者提供长期价值。

该集团也将整合多国组合策略，以多元化现金流创造市场如大马和新加坡的盈利来源、土耳其的中期增长势头、印度和大中华区的长期增长机会，以及专注于扩大现有业务并在中长期整合Fortis。

（编译：陈慧珊）

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2019	30 Jun 2018	30 Jun 2019	30 Jun 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,645,335	2,659,716	7,288,022	5,514,669
2	Profit/(loss) before tax	265,644	166,425	452,730	256,303
3	Profit/(loss) for the period	201,917	104,487	192,975	133,638
4	Profit/(loss) attributable to ordinary equity holders of the parent	184,994	165,106	274,504	222,341
5	Basic earnings/(loss) per share (Subunit)	1.86	1.75	2.63	2.19
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.5300		2.5100

icy97

ihh医保-下半年盈利唱好
https://www.enanyang.my/news/20190903/ihh医保-br下半年盈利唱好/

icy97

次季获利逊预期·IHH展望分歧
https://www.sinchew.com.my/content/content_2111307.html

（吉隆坡4日讯）IHH医保（IHH,5225,主板医疗保健组）第二季盈利表现低于市场预期，分析员对其展望看法分歧，正负皆有。

大众研究表示，虽然IHH核心营运盈利下滑，但未来仍有成长利好，主要是来所有主要市场皆可取得成长，盈利有望推高。

艾芬黄氏研究补充，除了印度业务，IHH主要市场皆取得内部成长，各地市场营业额成长介于12至22%。并相信未来内部仍可继续成长，主要是使用更多医疗服务，包括人口老化、富裕阶层增加、非传染性疾病及医疗旅游成长、香港业务亏损收窄、印度富通医疗（FORTIS）持续改善不断。

大众补充，香港业务第二季亏损从4270万令吉收窄至3450万令吉，入住率按季从68%减至62%，不过，这并非是当地政治风波导致，而是季节性因素，不少医生在6月休假。目前，香港病患多于中国病患。

丰隆研究亦认为，香港政治风波并不影响营运，且成都鹰阁医院（Gleneagle）最迟在今年投运，符合进展，而上海鹰阁医院则暂定2020财政年投运。

肯纳格研究与马银行研究看法较谨慎。

肯纳格最看淡I H H前景，主因外汇动荡，IHH今年4月已将土耳其Acibadem医院的美元债务减少2亿5000万美元（约10亿5600万令吉），仍有3亿美元债务待缴付，预期2020年落实。

另外，印度富通医疗也有进行拨备的忧虑，包括内部控制无法达标及监管因素，可能导致富通无法及时达到收支平衡或盈利贡献。

肯纳格补充，Acibadem业务贡献较少，IHH盈利亦会减少，因此将今明两财政年的盈利预测下调2%及3%，目标价一并调低。

马银行纳入贬值因素及采用综合估值法考量后，决定将2019至2021财政年的每股净利调低7%，目标价亦调低。





作者 ： 谢汪潮
文章来源 ： 星洲日报 2019-09-05

icy97

增长快-回酬稳-ihh相中印度中国
https://www.enanyang.my/news/20190912/增长快-回酬稳-brihh相中印度中国/

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) RELATED PARTY TRANSACTIONS
Description	IHH HEALTHCARE BERHAD ("IHH")PROPOSED ACQUISITION OF THE ENTIRE ISSUED SHARE CAPITAL OF PRINCE COURT MEDICAL CENTRE SDN BHD BY PANTAI HOLDINGS SDN BHD ("PHSB"), AN INDIRECT WHOLLY-OWNED SUBSIDIARY OF IHH FROM PULAU MEMUTIK VENTURES SDN BHD ("PMV"), A WHOLLY-OWNED SUBSIDIARY OF KHAZANAH NASIONAL BERHAD FOR A CASH CONSIDERATION OF RM1,020.0 MILLION ("PROPOSED ACQUISITION")
On behalf of the Board of Directors of IHH, Maybank Investment Bank Berhad wishes to announce that PHSB has on 17 September 2019 entered into a conditional share purchase agreement with PMV for the Proposed Acquisition. Please refer to the attached announcement for further details of the Proposed Acquisition. This Announcement is dated 17 September 2019.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6284641

Attachments IHH Announcement - Proposed Acquisition.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2019	30 Sep 2018	30 Sep 2019	30 Sep 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,788,364	2,840,915	11,076,386	8,355,584
2	Profit/(loss) before tax	394,263	-316,711	846,993	-60,408
3	Profit/(loss) for the period	281,850	-354,465	474,825	-220,827
4	Profit/(loss) attributable to ordinary equity holders of the parent	236,342	-104,071	510,846	118,270
5	Basic earnings/(loss) per share (Subunit)	2.44	-1.53	5.07	0.67
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.5400		2.5100

icy97

IHH HEALTHCARE BERHAD

Date of change	01 Jan 2020
Name	DR KELVIN LOH CHI-KEON
Age	46
Gender	Male
Nationality	Singapore
Type of change	Redesignation
Previous Position	Executive Director
New Position	Managing Director
Directorate	Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Masters	Business Administration	National University of Singapore Business School
2	Degree	Bachelor of Medicine and Bachelor of Surgery	National University of Singapore

Working experience and occupation	Dr Kelvin Loh Chi-Keon ("Dr Kelvin Loh") joined IHH Healthcare Berhad ("IHH") on 1 July 2019 as Chief Executive Officer ("CEO") (designate) and Executive Director from Columbia Asia Group where he was CEO. Presently, he also serves on the Boards and Board Committees of IHH subsidiaries, namely Parkway Pantai Limited, Fortis Healthcare Limited, SRL Limited and Acibadem Saglik Yatirimlari Holding A.S. Group. Dr Kelvin Loh started his career as a practicing physician before serving for 10 years in the public sector in Singapore, in areas such as clinical services development, hospital planning and hospital operations. Dr Kelvin Loh previously joined the IHH Group in 2008, and between 2008 and 2017 held a number of senior management roles, before taking over as CEO for the Singapore Operations Division, covering among other services, the 4 multi-specialty tertiary hospitals - Mount Elizabeth, Mount Elizabeth Novena, Gleneagles and Parkway East.Dr Kelvin Loh moved to Columbia Asia Group as CEO in 2017 where he was responsible for overseeing Columbia Asia Group's 28 hospitals across 4 countries in Asia including Malaysia and India. Dr Kelvin Loh is a senior healthcare executive with strong track record of delivery. He has extensive experience in leading large healthcare businesses, building relationships with stakeholders, managing hospital operations, financial management and developing people. He is also deeply familiar with the healthcare operating context in diverse countries across Asia.
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	Dr Kelvin Loh's interest as at 31 December 2019 is as follows: Direct interest in a subsidiary:Parkway Life Real Estate Investment Trust - 120,000 units

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Dec 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Dec 2019	31 Dec 2018	31 Dec 2019	31 Dec 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,836,099	3,165,348	14,912,485	11,520,932
2	Profit/(loss) before tax	195,731	812,878	1,042,724	752,470
3	Profit/(loss) for the period	40,017	710,687	514,842	489,860
4	Profit/(loss) attributable to ordinary equity holders of the parent	40,630	509,417	551,476	627,687
5	Basic earnings/(loss) per share (Subunit)	0.21	5.78	5.28	6.54
6	Proposed/Declared dividend per share (Subunit)	4.00	3.00	4.00	3.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.5500		2.5100

icy97

Type	Announcement
Subject	OTHERS
Description	Revaluation of Investment Properties
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3029213

Attachments IHH_Revaluation of Investment Properties (28.02.2020).pdf

icy97

IHH HEALTHCARE BERHAD

Entitlement subject	First and Final Dividend
Entitlement description	A first and final single tier cash dividend of MYR0.04 per ordinary share for the financial year ended 31 December 2019
Ex-Date	30 Mar 2020
Entitlement date	31 Mar 2020
Entitlement time	5:00 PM
Financial Year End	31 Dec 2019
Period
Share transfer book & register of members will be	to  closed from (both dates inclusive) for the purpose of determining the entitlement
Payment Date	30 Apr 2020
a.Securities transferred into the Depositor's Securities Account before 4:30 pm in respect of transfers	31 Mar 2020
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Announced Currency	Malaysian Ringgit (MYR)
Disbursed Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	Malaysian Ringgit (MYR) 0.0400

icy97

Type	Announcement
Subject	AUDIT REPORT - MODIFIED OPINION / MATERIAL UNCERTAINTY RELATED TO GOING CONCERN QUALIFIED OPINION
Description	Qualified Opinion on the Audited Financial Statements for the financial year ended 31 December 2019
https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3039473

Attachments IHH Announcement - Audit Report_Qualified Opinion.pdf

pts2222

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,555,176	3,642,687	3,555,176	3,642,687
2	Profit/(loss) before tax	-257,357	187,086	-257,357	187,086
3	Profit/(loss) for the period	-366,660	-8,942	-366,660	-8,942
4	Profit/(loss) attributable to ordinary equity holders of the parent	-319,786	89,510	-319,786	89,510
5	Basic earnings/(loss) per share (Subunit)	-3.90	0.78	-3.90	0.78
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	2.4500		2.5500

吉隆坡30日讯）IHH医疗保健（IHH Healthcare Bhd）今早一度下跌13仙或2.32%，至5.47令吉，因该集团昨日宣布首季净亏3亿1979万令吉及营业额下滑。

IHH昨日表示，截至今年3月杪首季净亏3亿1979万令吉，一年前则净赚8951万令吉。营业额从36亿4000万令吉，降至35亿6000万令吉

https://www.orientaldaily.com.my/news/business/2020/06/29/349044